UNSPSC 51113501: Pipobroman

This classification denotes an antineoplastic alkylating agent with the molecular formula C10H16Br2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q99RDT97R, chemically known as 1,4-bis(3-bromopropionyl)piperazine but more generally known as pipobroman, which bears US NIH Compound Identifier 4842. European Medicines Agency schedules Pipobroman in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09875MIG. The term PIPOBROMAN is an International Non-Proprietary Name.

UNSPSC 51113501 Pipobroman, a Commodity code, covers pharmaceutical products for therapeutic use that state and local governments procure primarily through their health and human services agencies. State and local health authorities, Medicaid programs, and employee health benefit administrators use this code to acquire specific pharmaceutical agents — in recent activity, the code appears tagged to procurement related to direct-to-manufacturer prescription fulfillment and pharmacy benefit program optimization. The issuing bodies under this code are state-level health and human services departments and related agencies managing pharmacy benefit programs, employee health plans, and Medicaid pharmacy services on behalf of beneficiary populations.

The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities regarding implementation of a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI seeks information from vendors about establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management, including vendors' experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on negotiated net pricing models, and capability to implement value-based or outcomes-based agreements. No award value or budget range is identified at this exploratory stage; the RFI is designed to inform the state's future procurement strategy before issuing a formal RFP with established financial and temporal parameters.